再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

REGN 再生元制药公司

休市中 01-16 16:00:00 EST

733.04

-8.88

-1.20%

盘后733.04

+0.000.00%

19:40 EST

最高749.09	最低726.43	成交量168.26万
今开749.09	昨收741.92	日振幅3.05%
总市值770.42亿	流通市值757.25亿	总股本1.05亿
成交额12.35亿	换手率1.63%	流通股本1.03亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"再生元制药公司","latestPrice":733.04,"timestamp":1768597200000,"preClose":741.92,"halted":0,"volume":1682566,"hourTrading":{"tag":"盘后","latestPrice":733.04,"preClose":733.04,"latestTime":"19:40 EST","volume":468741,"amount":343611002.32322,"timestamp":1768610431146,"change":0,"changeRate":0,"amplitude":0.004188},"delay":0,"changeRate":-0.011968945438861327,"floatShares":103302739,"shares":105099464,"eps":41.59414,"marketStatus":"休市中","change":-8.88,"latestTime":"01-16 16:00:00 EST","open":749.09,"high":749.09,"low":726.43,"amount":1234600469.443,"amplitude":0.030542,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":41.59414,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1768899600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":741.92,"dividendRate":0.004802,"preHourTrading":{"tag":"盘前","latestPrice":744.28,"preClose":741.92,"latestTime":"09:29 EST","volume":14483,"amount":10745341.775700001,"timestamp":1768573774679,"change":2.36,"changeRate":0.003181,"amplitude":0.015204},"postHourTrading":{"tag":"盘后","latestPrice":733.04,"preClose":733.04,"latestTime":"19:40 EST","volume":468741,"amount":343611002.32322,"timestamp":1768610431146,"change":0,"changeRate":0,"amplitude":0.004188},"volumeRatio":1.8635884050891534,"impliedVol":0.381,"impliedVolPercentile":0.4343},"requestUrl":"/m/hq/s/REGN","defaultTab":"news","newsList":[{"id":"2603685535","title":"再生元制药公司涨0.27% 股价突破800美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2603685535","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603685535?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:31","pubTimestamp":1768228293,"startTime":"0","endTime":"0","summary":"北京时间2026年01月12日22时31分，再生元制药公司股票出现波动，股价急速上涨0.27%。截至发稿，该股报798.72美元/股，成交量4.3729万股，换手率0.04%，振幅1.95%。机构评级方面，在所有30家参与评级的机构中，70%的券商给予买入建议，30%的券商给予持有建议，无券商给予卖出建议。再生元制药公司股票所在的生物技术行业中，整体跌幅为0.64%。再生元制药公司公司简介：再生元制药发现、开发并商业化对抗眼病、心血管疾病、癌症和炎症的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112223134a4bb0ea1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112223134a4bb0ea1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0823434740.USD","LU0053666078.USD","LU2237438978.USD","LU2468319806.SGD","BK4585","LU2362541273.HKD","LU2362540622.SGD","BK4139","LU0823416689.USD","LU2089984988.USD","LU2106854487.HKD","LU0889565916.HKD","LU0109394709.USD","LU0114720955.EUR","LU0823434583.USD","LU2362541513.USD","REGN","BK4588","LU0882574055.USD","LU2023250504.SGD","LU0320765992.SGD","LU1974910355.USD","LU0289739699.SGD","LU1917777945.USD","LU0058720904.USD"],"gpt_icon":0},{"id":"1183550675","title":"再生元制药公司：IPR&D费用将导致2025年第四季度调整后每股收益减少0.14美元——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1183550675","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183550675?lang=zh_cn&edition=full","pubTime":"2026-01-12 19:51","pubTimestamp":1768218682,"startTime":"0","endTime":"0","summary":"根据最新提交的美国证券交易委员会（SEC）文件显示，再生元制药公司确认，一项与IPR&D（进程中的研发项目）相关的费用，预计将对2025年第四季度的调整后每股收益产生负面影响，具体减少金额为0.14美元。\n这一费用反映了公司在研发领域的持续投入与战略调整。尽管短期内会对盈利指标造成压力，但它也凸显了再生元制药长期致力于创新药物开发的决心。投资者在评估公司未来业绩时，需综合考虑此类战略性支出对长期价值创造的潜在贡献。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","BK4585","LU0823416689.USD","LU0114720955.EUR","LU0109394709.USD","LU2362541273.HKD","LU0882574055.USD","BK4588","LU2362541513.USD","LU0053666078.USD","LU0823434740.USD","LU1974910355.USD","LU2106854487.HKD","LU2237438978.USD","LU2468319806.SGD","LU1917777945.USD","REGN","LU2023250504.SGD","LU0320765992.SGD","BK4139","LU2362540622.SGD","LU0289739699.SGD","LU0823434583.USD","LU0889565916.HKD","LU2089984988.USD"],"gpt_icon":0},{"id":"2602450584","title":"再生元制药公司跌0.13% 股价跌破800美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2602450584","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602450584?lang=zh_cn&edition=full","pubTime":"2026-01-10 00:36","pubTimestamp":1767976611,"startTime":"0","endTime":"0","summary":"北京时间2026年01月10日00时36分，再生元制药公司股票出现波动，股价快速跳水0.13%。截至发稿，该股报800.00美元/股，成交量25.4784万股，换手率0.24%，振幅2.62%。最近的财报数据显示，该股实现营业收入37.54亿美元，净利润14.60亿美元，每股收益14.09美元，毛利30.96亿美元，市盈率19.18倍。再生元制药公司股票所在的生物技术行业中，整体涨幅为0.75%。再生元制药公司公司简介：再生元制药发现、开发并商业化对抗眼病、心血管疾病、癌症和炎症的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260110003651a7081e1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260110003651a7081e1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","LU0889565916.HKD","LU2237438978.USD","LU1917777945.USD","LU2362541513.USD","LU2023250504.SGD","LU2362540622.SGD","LU0823434583.USD","BK4588","REGN","LU0289739699.SGD","LU2089984988.USD","LU2362541273.HKD","LU2468319806.SGD","LU0823416689.USD","LU2106854487.HKD","LU0053666078.USD","LU0109394709.USD","BK4139","LU0823434740.USD","LU0114720955.EUR","LU0882574055.USD","LU1974910355.USD","BK4585","LU0058720904.USD"],"gpt_icon":0},{"id":"1103404064","title":"再生元制药公司获美银全球研究上调评级至“买入” 盘前股价应声上涨2.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1103404064","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103404064?lang=zh_cn&edition=full","pubTime":"2026-01-07 19:37","pubTimestamp":1767785828,"startTime":"0","endTime":"0","summary":"在美银全球研究将其股票评级从“跑输大盘”上调至“买入”后，再生元制药公司（Regeneron Pharmaceuticals）股价在盘前交易时段应声走高，涨幅达2.3%。\n此次评级上调反映了市场对该公司前景的积极预期转变，并直接提振了投资者信心，推动其股价在开盘前显著上扬。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541273.HKD","LU0114720955.EUR","LU0289739699.SGD","LU2362541513.USD","LU2468319806.SGD","BK4588","LU0823434740.USD","LU0320765992.SGD","LU2237438978.USD","REGN","LU0109394709.USD","LU2106854487.HKD","LU2089984988.USD","BK4585","LU0823416689.USD","LU0889565916.HKD","LU2023250504.SGD","LU1974910355.USD","BK4139","LU1917777945.USD","LU0823434583.USD","LU0058720904.USD","LU2362540622.SGD","LU0882574055.USD","LU0053666078.USD"],"gpt_icon":0},{"id":"1187319297","title":"美银全球研究上调再生元制药评级至买入 目标价跃升至860美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1187319297","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187319297?lang=zh_cn&edition=full","pubTime":"2026-01-07 19:27","pubTimestamp":1767785239,"startTime":"0","endTime":"0","summary":"美银全球研究（Bofa Global Research）发布最新报告，将再生元制药公司的投资评级从\"表现不佳\"大幅上调至\"买入\"级别。与此同时，该机构将其目标股价从每股627美元显著提升至860美元，显示出对该公司未来业绩的强劲信心。\n此次评级调整反映了分析师对再生元制药核心业务增长潜力的重新评估。目标价的大幅上调表明，美银全球研究认为该公司在医药研发领域的领先地位，以及其创新药物管线的商业价值尚未被市场充分定价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237438978.USD","REGN","LU0823434740.USD","LU0289739699.SGD","LU0320765992.SGD","LU1917777945.USD","LU0882574055.USD","LU2362541273.HKD","LU2089984988.USD","LU2468319806.SGD","LU2106854487.HKD","LU0109394709.USD","BK4585","BK4139","LU0058720904.USD","BK4588","LU0114720955.EUR","LU0889565916.HKD","LU0823416689.USD","LU1974910355.USD","LU2362540622.SGD","LU0823434583.USD","LU2362541513.USD","LU0053666078.USD","LU2023250504.SGD"],"gpt_icon":0},{"id":"1165078073","title":"新闻发布：赛诺菲与再生元制药公司的Dupixent在日本获得批准，用于6至11岁支气管哮喘儿童的治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1165078073","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165078073?lang=zh_cn&edition=full","pubTime":"2025-12-23 14:06","pubTimestamp":1766469989,"startTime":"0","endTime":"0","summary":"新闻发布：赛诺菲与再生元制药公司的Dupixent在日本获得批准，用于6至11岁支气管哮喘儿童的治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023250504.SGD","LU1974910355.USD","LU0823434740.USD","BK4585","LU1917777945.USD","LU0289739699.SGD","LU0114720955.EUR","LU0058720904.USD","REGN","LU0823416689.USD","BK4139","LU2089984988.USD","LU2106854487.HKD","LU2468319806.SGD","LU0882574055.USD","LU2362540622.SGD","LU2362541273.HKD","LU0053666078.USD","LU0109394709.USD","LU2237438978.USD","LU0320765992.SGD","LU0823434583.USD","BK4588","LU0889565916.HKD","LU2362541513.USD"],"gpt_icon":0},{"id":"2592139231","title":"默沙东(MRK.US)、施贵宝(BMY.US)等多家药企同意下调美国药价 以换取特朗普政府关税豁免和政策支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2592139231","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592139231?lang=zh_cn&edition=full","pubTime":"2025-12-20 07:00","pubTimestamp":1766185200,"startTime":"0","endTime":"0","summary":"美国总统特朗普推动将美国药价与海外低价市场挂钩之际，多家美国及欧洲大型制药企业近日与白宫达成协议，同意自愿下调在美销售的药品价格，以换取关税豁免和政策支持。在此次协议中，最受市场关注的是施贵宝的让利承诺。特朗普在周五的公开活动上表示，今年7月他致信要求降价的17家大型制药企业中，已有14家同意大幅下调药价。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2acbaf8fbf691a451fa9ea170ee88816","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384042.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0477156953.USD","IE00BJT1NW94.SGD","LU1066051811.HKD","LU1989771016.USD","LU1032466523.USD","LU0861579265.USD","LU1291159041.SGD","LU0265550946.USD","LU0208291251.USD","LU0320765489.SGD","LU1061106388.HKD","LU0306806265.USD","LU1868836591.USD","IE00BSNM7G36.USD","IE0009355771.USD","ABBV","BK4533","BK4532","LU0320765646.SGD","SG9999001176.SGD","SG9999015341.SGD","LU1261432733.SGD","IE00B4R5TH58.HKD","LU2089984988.USD","LU0114720955.EUR","LU1037948541.HKD","AMGN","IE00B1BXHZ80.USD","LU1585245621.USD","LU0130102774.USD","LU1093756168.USD","SG9999002232.USD","IE000M9KFDE8.USD","LU0096364046.USD","LU0965509283.SGD","LU0306807586.USD","LU1571399168.USD","LU2106854487.HKD","LU0321505868.SGD","LU1917777945.USD","LU1069347547.HKD","LU1941712264.USD","LU0882574055.USD","LU1868837136.USD","LU1093756325.SGD","LU2125154935.USD","IE00BLSP4452.SGD","LU1941712348.USD","LU0456855351.SGD","IE00BBT3K403.USD","LU0122379950.USD","LU2361045086.USD","LU1989772840.SGD","SG9999001440.SGD","SG9999014542.SGD","IE00BFXG1179.USD","LU2112291526.USD","LU0058720904.USD","BK4516","LU1116320737.USD","LU1670711123.USD","LU1983299246.USD","LU1929549753.HKD","AZN","LU0070302665.USD","LU1868836757.USD","LU2324357040.USD","LU1868837300.USD","LU0648001328.SGD","IE00B2B36J28.USD","LU1162221912.USD","LU0980610538.SGD","LU2242646821.SGD","04332","LU0265550359.USD","LU1974910355.USD","SG9999002224.SGD","LU1023059063.AUD","LU1934455194.USD","SG9999001176.USD","LU0203347892.USD","ROG","LU1074936037.SGD","BK4581","LU0965509101.SGD","IE00BFTCPJ56.SGD","LU2360032135.SGD","LU0211331839.USD","IE00BN8TJ469.HKD","LU0985481810.HKD","LU0266013472.USD","SG9999014575.USD","LU0289739699.SGD","LU2023250843.SGD","LU1201861249.SGD","LU0985320562.USD","LU1323610961.USD","LU2023250504.SGD","LU2361044865.SGD","BK4559","LU2461242641.AUD","LU1989772923.USD","BK4550","LU2468319806.SGD","LU2361044949.HKD","LU0321505439.SGD","LU0238689110.USD","LU1670710588.SGD","SG9999015358.SGD","BK4007","IE00BJJMRZ35.SGD","LU1057294990.SGD","LU0965508806.USD","JNJ","LU0106261372.USD","NVS","GILD","IE00BLSP4239.USD","LU1066053197.SGD","SNY","LU0098860793.USD","LU1934455863.HKD","LU2125154778.USD","LU1699723380.USD","BK4588","LU0237698245.USD","LU1035773651.USD","LU0267386448.USD","SG9999014567.USD","LU0130517989.USD","MRK","LU1116320901.HKD","LU0868494617.USD","BK4585","LU1670710661.SGD","LU2242652126.USD","LU1934455277.USD","LU0203345920.USD","BK4534","LU1718418525.SGD","LU1066051225.USD","LU0965509010.AUD","GSK","LU0225771236.USD","SG9999014559.SGD","LU1430594728.SGD","LU2133065610.SGD","LU0061475181.USD","LU0006306889.USD","BMY","LU1037948897.HKD","SG9999013999.USD","LU1670711040.USD","LU1066051498.USD","SGXZ57979304.SGD","REGN","LU1868836914.USD","LU0234572021.USD","IE0002141913.USD","LU0225284248.USD"],"gpt_icon":1},{"id":"1164632612","title":"欧洲药品管理局推荐扩展Arexvy、Aspaveli、Dovprela、Elucirem、Eylea、Nucala、Recarbrio、Simponi、Uplizna、Vueway的适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=1164632612","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164632612?lang=zh_cn&edition=full","pubTime":"2025-12-12 21:50","pubTimestamp":1765547422,"startTime":"0","endTime":"0","summary":"欧洲药品管理局（Ema）的药物评审委员会（Chmp）推荐扩展以下药物的适应症：Arexvy、Aspaveli、Dovprela、Elucirem、Eylea、Nucala、Recarbrio、Simponi、Uplizna和Vueway。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00BLSP4452.SGD","LU0965509010.AUD","LU1035773651.USD","LU1929549753.HKD","LU1941712264.USD","LU0130517989.USD","LU2324357040.USD","LU1066053197.SGD","LU2430703251.USD","SG9999001176.USD","LU1674673428.USD","IE00B19Z3B42.SGD","IE00BFXG1179.USD","LU0130102774.USD","LU0477156953.USD","LU0823434583.USD","LU0861579265.USD","SGXZ57979304.SGD","LU2023250504.SGD","LU0321505439.SGD","LU1914381329.SGD","SG9999014559.SGD","BK4516","LU0889566641.SGD","LU0320765489.SGD","LU0648001328.SGD","LU1934455277.USD","BK4568","LU0787776722.HKD","LU1989772923.USD","LU1974910355.USD","BK4592","LU1571399168.USD","LU1032466523.USD","LU1093756168.USD","LU1037948541.HKD","LU1934455863.HKD","LU0203345920.USD","IE00BWDBJ516.SGD","LU1934455194.USD","LU0208291251.USD","LU2505996509.AUD","LU1400636657.SGD","LU1162221912.USD","MRK","LU0225771236.USD","LU0006306889.USD","LU1202635105.USD","LU1487256676.USD","LU2133065610.SGD","LU1196500208.SGD","IE00BJJMRZ35.SGD","LU1732799900.SGD","LU0345769128.USD","IE00BBT3K403.USD","LU1585245621.USD","LU2471134796.USD","IE0034235071.USD","LU0070302665.USD","LU1098665638.USD","LU1989772840.SGD","LU0203347892.USD","LU0289739699.SGD","LU0792757196.USD","LU2430703095.HKD","GSK.UK","REGN","LU0109394709.USD","LU0106261372.USD","LU2360032135.SGD","IE00B42XCP33.USD","LU0098860793.USD","LU0912757837.SGD","LU1116320737.USD","LU0889565916.HKD","LU1699723380.USD","LU0161305163.EUR","LU0795875086.SGD","LU2347655156.SGD","LU2023250843.SGD","SG9999015341.SGD","LU2505996681.GBP","BK4139","LU0265550946.USD","LU0683600562.USD","LU1116320901.HKD","SG9999002224.SGD","LU0266013472.USD","IE00BQJZX424.USD","IE00BSNM7G36.USD","IE00BGHQF631.EUR","LU2112291526.USD","BK4532","LU2461242641.AUD","LU2468319806.SGD","LU0882574055.USD","LU1291159041.SGD","LU0122379950.USD","LU2129689605.HKD","LU1228905540.USD","LU2750360997.AUD","LU0345770993.USD","LU1261432733.SGD","IE00B3PB1722.GBP","LU1061106388.HKD","LU1064927863.SGD","LU1244550577.SGD","LU0965509283.SGD","LU1400636574.HKD","LU1066051498.USD","LU1074936037.SGD","LU0109981661.USD","BK4588","LU0321505868.SGD","LU1201861249.SGD","LU2362540622.SGD","LU0058720904.USD","LU0795875169.SGD","LU1023059063.AUD","BK4534","LU1718418525.SGD","LU1066051811.HKD","LU0211331839.USD","LU1732800096.USD","IE0034235303.USD","LU0345769631.USD","IE000M9KFDE8.USD","LU0823416689.USD","LU1506573853.SGD","LU1059921491.USD","LU1935042991.SGD","LU2361044949.HKD","LU0980610538.SGD","LU0985481810.HKD","LU1309081286.SGD","LU1989771016.USD","IE00B7SZLL34.SGD","LU1894683348.USD","LU1941712348.USD","LU1066051225.USD","LU2592432038.USD","LU0320765646.SGD","LU0124676726.USD","BK5011","LU0114720955.EUR","BK4559","LU0345770308.USD","LU1046248800.SGD","LU2362541273.HKD","LU1983299246.USD","LU2106854487.HKD","LU2362541513.USD","LU2089984988.USD","LU1917777945.USD","JNJ","LU0306807586.USD","LU1280957306.USD","LU2602419157.SGD","IE0002141913.USD","LU2471134879.HKD","IE00BFTCPJ56.SGD","LU2125154778.USD","BK4581","LU1221951129.SGD","LU1244550221.USD","LU1400636491.USD","LU0070217475.USD","LU2750360641.GBP","LU0971552830.HKD","LU0545562505.USD","IE0002270589.USD","SG9999002232.USD","LU0965508806.USD","IE00BLSP4239.USD","LU0265550359.USD","LU1674673691.USD","LU2361045086.USD","SG9999014575.USD","SG9999001176.SGD","LU0575583348.USD","IE00B1BXHZ80.USD","LU1645745479.HKD","LU1430594728.SGD","LU1670756490.USD","LU1302929846.USD","LU0985320562.USD","BK4007","LU1035777561.USD","LU0053666078.USD","LU1093756325.SGD","LU0238689110.USD","LU1228905037.USD","IE00B4R5TH58.HKD","LU0225284248.USD","IE00BN8TJ469.HKD","LU2125154935.USD","LU2237438978.USD","IE00B2B36J28.USD","LU1221951046.USD","LU2430703178.SGD","LU1037948897.HKD","LU1894683264.USD","LU2471134952.CNY","LU0965509101.SGD","LU0306806265.USD","LU2361044865.SGD","IE00B3T34201.USD","LU0432979614.USD","LU2129689431.USD","LU1778281490.HKD","LU0466842654.USD","LU0823434740.USD","BK4550","LU0640476718.USD","LU2129689514.USD","IE00BZ1G4Q59.USD","LU1057294990.SGD","LU1481600234.SGD","SG9999013999.USD","SG9999014542.SGD","IE00BVYPNV92.GBP","LU1015430645.USD","LU0320765992.SGD","SG9999001440.SGD","BK4533","IE00BVYPNW00.USD","IE00BKVL7J92.USD","LU2471134523.USD","SG9999014567.USD","LU1481599808.USD","LU1032955483.USD","LU1069347547.HKD","IE00BDGV0183.EUR","LU0689626769.HKD","LU1267930813.SGD","LU0234570918.USD","SG9999015358.SGD","IE00BJT1NW94.SGD","LU1496350502.SGD","BK4585","LU0234572021.USD","BK4504","IE00B19Z3581.USD","LU1244550494.USD","LU0971552673.USD"],"gpt_icon":0},{"id":"1107092688","title":"独家：美国FDA促请审评员加快对礼来减肥药的评估 - 内部文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1107092688","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107092688?lang=zh_cn&edition=full","pubTime":"2025-12-12 19:01","pubTimestamp":1765537283,"startTime":"0","endTime":"0","summary":"独家：美国FDA促请审评员加快对礼来减肥药的评估 - 内部文件","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417517546.SGD","LU2237443382.USD","IE00BJJMRX11.SGD","LU2237443622.USD","LU0471298777.SGD","LU0823416689.USD","LU2112291526.USD","IE0005OL40V9.USD","LU0114720955.EUR","LU2089984988.USD","SG9999001176.USD","LU0471298694.HKD","LU1989771016.USD","LU1868836914.USD","LU2471134523.USD","LU0122379950.USD","SG9999018857.SGD","LU0094547139.USD","LU0053666078.USD","LU1917777945.USD","SG9999014880.SGD","SG9999017495.SGD","SGXZ99366536.SGD","LU2456880835.USD","LU2265009873.SGD","LU2237443549.SGD","LU1720051017.SGD","BK4534","LU0256863902.USD","GB00BDT5M118.USD","SG9999001176.SGD","IE00BJLML261.HKD","LU0109394709.USD","LU1804176565.USD","IE00B2B36J28.USD","LU2468319806.SGD","LU0889565916.HKD","LU2362540622.SGD","LU0109391861.USD","SGXZ31699556.SGD","LU2362541513.USD","LU0786609619.USD","LU1323610961.USD","LU2491049909.HKD","LU1093756325.SGD","LU1868836757.USD","LU2750360997.AUD","LU2108987350.USD","LU2237443895.HKD","LU0256863811.USD","LU0882574139.USD","LU2746668461.USD","LU0079474960.USD","LU2168564149.EUR","LU1232071149.USD","IE0002141913.USD","SG9999015952.SGD","LLY","SGXZ57979304.SGD","BK4533","LU2491050071.SGD","LU2168564495.EUR","LU0640476718.USD","IE00B4JS1V06.HKD","BK4516","IE00BJJMRY28.SGD","LU0097036916.USD","SGXZ81514606.USD","LU1061106388.HKD","LU0203201768.USD","LU0689472784.USD","LU1064131342.USD","IE00B1BXHZ80.USD","LU0096364046.USD","LU1093756168.USD","BK4599","LU1623119135.USD","LU1814569148.SGD","LU1551013425.SGD","LU2087625088.SGD","LU2168564065.EUR","LU1868837136.USD","LU0058720904.USD","LU0353189680.USD","LU0943347566.SGD","LU2471134796.USD","SG9999018865.SGD","LU0354030511.USD","IE00BK4W5L77.USD","LU2237438978.USD","LU2362541273.HKD","LU0203202063.USD","LU0385154629.USD","LU1548497426.USD","LU0320765992.SGD","IE00BJJMRZ35.SGD","LU2471134952.CNY","LU2552382132.HKD","BK4585","LU1868836591.USD","LU0353189763.USD","IE00B1XK9C88.USD","LU2023250504.SGD","LU0106261372.USD","LU1267930730.SGD","LU0466842654.USD","LU2471134879.HKD","LU2168563687.JPY","LU0823434583.USD","LU1280957306.USD","IE00BKDWB100.SGD","LU1366192091.USD","LU0316494557.USD","IE00B4R5TH58.HKD","LU2746668974.SGD","SG9999014914.USD","LU0061475181.USD","LU0289739699.SGD","LU1069344957.HKD","LU1868837300.USD","LU2211815571.USD","REGN","SG9999015945.SGD","LU0456855351.SGD","LU2324357040.USD","LU1023059063.AUD","IE00BFSS8Q28.SGD","LU0238689110.USD","LU2491050154.USD","LU2236285917.USD","IE00BFTCPJ56.SGD","LU2237443465.HKD","LU0787776722.HKD","IE0004445015.USD","BK4007","LU2357305700.SGD","IE0009355771.USD","LU1035775433.USD","SG9999015986.USD","LU2264538146.SGD","LU0234572021.USD","LU2360106947.USD","LU0820561909.HKD","LU2237443978.SGD","LU0323591593.USD","LU0198837287.USD","LU1988902786.USD","LU1057294990.SGD","LU0006306889.USD","LU2361045086.USD","IE00B7KXQ091.USD","SGXZ51526630.SGD","LU0820561818.USD","BK4588","IE00BK4W5M84.HKD","LU1551013342.USD","BK4139","BK4581","IE00BN29S564.USD","LU0882574055.USD","SG9999013999.USD","IE00BFSS7M15.SGD","LU1127390331.HKD","LU1720051108.HKD","LU2462157665.USD","LU0432979614.USD","LU2361044949.HKD","LU2417539215.USD","SG9999014898.SGD","LU2168564222.USD","LU0672654240.SGD","SG9999014906.USD","LU1712237335.SGD","IE0004445239.USD","LU2461242641.AUD","IE00BJT1NW94.SGD","LU1291159041.SGD","LU2063271972.USD","LU2106854487.HKD","IE00BKPKM429.USD","LU0823434740.USD","SG9999015978.USD","LU1974910355.USD","LU0266013472.USD","LU2361044865.SGD","IE00BWXC8680.SGD","LU2750360641.GBP","LU1983299246.USD","LU2552382215.SGD","LU0708995401.HKD","IE00B775H168.HKD","LU2602419157.SGD","LU0320765059.SGD","LU0683600562.USD","LU0354030438.USD","LU2552382058.USD"],"gpt_icon":0},{"id":"1123079494","title":"Lynozyfic™（Linvoseltamab）单药治疗新诊断多发性骨髓瘤（Ndmm）显著反应，支持作为一线治疗潜在基础的合理性","url":"https://stock-news.laohu8.com/highlight/detail?id=1123079494","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123079494?lang=zh_cn&edition=full","pubTime":"2025-12-08 05:32","pubTimestamp":1765143133,"startTime":"0","endTime":"0","summary":"Lynozyfic™（Linvoseltamab）单药治疗新诊断多发性骨髓瘤（Ndmm）显著反应，支持作为一线治疗潜在基础的合理性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023250504.SGD","BK4588","LU0823416689.USD","LU0114720955.EUR","LU2089984988.USD","BK4139","LU0882574055.USD","LU0053666078.USD","LU1917777945.USD","LU0289739699.SGD","REGN","LU0109394709.USD","LU2468319806.SGD","LU2106854487.HKD","LU0823434740.USD","LU0889565916.HKD","LU2362540622.SGD","LU0058720904.USD","LU1974910355.USD","LU2362541513.USD","LU2237438978.USD","LU2362541273.HKD","LU0320765992.SGD","BK4585","LU0823434583.USD"],"gpt_icon":0},{"id":"1185904287","title":"再生元制药公司：公司将50:50共享全球开发费用和未来利润","url":"https://stock-news.laohu8.com/highlight/detail?id=1185904287","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185904287?lang=zh_cn&edition=full","pubTime":"2025-12-01 20:01","pubTimestamp":1764590487,"startTime":"0","endTime":"0","summary":"再生元制药公司：公司将50:50共享全球开发费用和未来利润","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0109394709.USD","LU2362540622.SGD","LU2089984988.USD","LU2023250504.SGD","LU0823416689.USD","BK4588","LU2362541513.USD","LU0053666078.USD","LU0289739699.SGD","BK4139","REGN","LU2362541273.HKD","LU2106854487.HKD","LU0823434583.USD","LU1917777945.USD","LU2237438978.USD","LU0889565916.HKD","LU0114720955.EUR","LU2468319806.SGD","LU0882574055.USD","LU0320765992.SGD","LU0058720904.USD","LU0823434740.USD","LU1974910355.USD"],"gpt_icon":0},{"id":"1199264050","title":"再生元制药公司与Tessera Therapeutics联合开发针对α-1抗胰蛋白酶缺乏症的研究性基因编辑治疗Tsra-196","url":"https://stock-news.laohu8.com/highlight/detail?id=1199264050","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199264050?lang=zh_cn&edition=full","pubTime":"2025-12-01 20:01","pubTimestamp":1764590470,"startTime":"0","endTime":"0","summary":"再生元制药公司与Tessera Therapeutics联合开发针对α-1抗胰蛋白酶缺乏症的研究性基因编辑治疗Tsra-196。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1974910355.USD","LU0823434740.USD","LU1917777945.USD","LU2106854487.HKD","BK4139","LU0823434583.USD","LU0889565916.HKD","LU0320765992.SGD","LU0823416689.USD","LU2237438978.USD","LU2362541273.HKD","LU0882574055.USD","BK4585","BK4588","LU0114720955.EUR","LU0109394709.USD","LU2089984988.USD","LU0058720904.USD","LU2362540622.SGD","LU0289739699.SGD","LU2468319806.SGD","LU2023250504.SGD","LU0053666078.USD","LU2362541513.USD","REGN"],"gpt_icon":0},{"id":"2586442054","title":"汇丰：首予再生元制药(REGN.US)“买入”评级 看好Eylea HD放量及肿瘤管线多点催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2586442054","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586442054?lang=zh_cn&edition=full","pubTime":"2025-11-25 15:32","pubTimestamp":1764055926,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，汇丰银行发表研报，首次覆盖再生元制药，并给予 “买入” 评级，目标价为890美元，核心依据包括其药物Eylea HD明年销售额的增长潜力，以及研发管线中多项癌症疗法的积极催化。分析师Yifeng Liu指出，尽管Eylea HD目前的市场渗透速度未达预期，但“与Eylea HD相关的监管风险有望在短期内得到解决，这将为2026年药物加速普及和渗透率提升奠定基础”。此外，该联合疗法用于黑色素瘤辅助治疗的III期临床数据可能于明年公布。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373216.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HD","HSBC","01477","REGN"],"gpt_icon":0},{"id":"1159316672","title":"新闻稿：Dupixent，由赛诺菲和再生元制药公司开发，成为十多年来欧盟首个针对特发性慢性荨麻疹的靶向药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1159316672","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159316672?lang=zh_cn&edition=full","pubTime":"2025-11-25 14:00","pubTimestamp":1764050418,"startTime":"0","endTime":"0","summary":"新闻稿：Dupixent，由赛诺菲和再生元制药公司开发，成为十多年来欧盟首个针对特发性慢性荨麻疹的靶向药物","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541273.HKD","LU0114720955.EUR","LU0289739699.SGD","LU2362541513.USD","LU2468319806.SGD","BK4588","LU0823434740.USD","LU0320765992.SGD","LU2237438978.USD","REGN","LU0109394709.USD","LU2106854487.HKD","LU2089984988.USD","BK4585","LU0823416689.USD","LU0889565916.HKD","LU2023250504.SGD","LU1974910355.USD","BK4139","LU1917777945.USD","LU0823434583.USD","LU0058720904.USD","LU2362540622.SGD","LU0882574055.USD","LU0053666078.USD"],"gpt_icon":0},{"id":"1145897938","title":"Dupixent®（Dupilumab）成为十多年来欧洲联盟（EU）首个获批的针对慢性自发性荨麻疹（CSU）的靶向药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1145897938","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145897938?lang=zh_cn&edition=full","pubTime":"2025-11-25 14:00","pubTimestamp":1764050415,"startTime":"0","endTime":"0","summary":"Dupixent®（Dupilumab）成为十多年来欧洲联盟（EU）首个获批的针对慢性自发性荨麻疹（CSU）的靶向药物","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1917777945.USD","LU1974910355.USD","LU0882574055.USD","BK4588","LU2362540622.SGD","BK4585","LU0289739699.SGD","LU0058720904.USD","LU0053666078.USD","LU2023250504.SGD","BK4139","LU0823434583.USD","LU2237438978.USD","LU2089984988.USD","LU0114720955.EUR","LU2468319806.SGD","LU2362541273.HKD","LU2362541513.USD","LU0889565916.HKD","LU0823434740.USD","REGN","LU0823416689.USD","LU0320765992.SGD","LU2106854487.HKD","LU0109394709.USD"],"gpt_icon":0},{"id":"1142970680","title":"一周美股牛榜 | 再生元上周飙升9%；谷歌和罗斯百货扬8%；美敦力升6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1142970680","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142970680?lang=zh_cn&edition=full","pubTime":"2025-11-24 10:17","pubTimestamp":1763950659,"startTime":"0","endTime":"0","summary":"Solventum董事会已批准一项 股票回购计划，授权公司回购 最多10亿美元 的普通股。Solventum股价上周上涨 9.6%。谷歌A上周五收涨 3.5%，市值达到 3.62万亿美元，上周股价大涨 8.4%。公司第三季度销售也超出预期，上周股价上涨 8.4%。美敦力上调全年销售增长预期，因心脏设备需求强劲 $美敦力$ 第二财季业绩超出预期，并在上周二上调全年销售增长预期，因心脏设备需求旺盛，股价上周上涨 5.6%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/226b03648204ea05089b5982a628b9f4","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/226b03648204ea05089b5982a628b9f4"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDT","ROST","GOOGL","REGN"],"gpt_icon":1},{"id":"1140117891","title":"再生元制药公司 - 与Catalent Indiana协调解决2025年7月FDA一般现场检查中发现的问题","url":"https://stock-news.laohu8.com/highlight/detail?id=1140117891","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140117891?lang=zh_cn&edition=full","pubTime":"2025-11-20 05:12","pubTimestamp":1763586732,"startTime":"0","endTime":"0","summary":"再生元制药公司 - 与Catalent Indiana协调解决2025年7月FDA一般现场检查中发现的问题","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","LU2362541273.HKD","LU0320765992.SGD","LU0109394709.USD","LU2362540622.SGD","LU2237438978.USD","LU0889565916.HKD","BK4588","LU1974910355.USD","LU0053666078.USD","BK4139","REGN","LU0289739699.SGD","LU0114720955.EUR","LU0058720904.USD","LU0823434583.USD","LU1917777945.USD","LU0823434740.USD","LU0882574055.USD","LU2362541513.USD","BK4585","LU2106854487.HKD","LU2089984988.USD","LU2023250504.SGD","LU0823416689.USD"],"gpt_icon":0},{"id":"1132722384","title":"Eylea Hd® (Aflibercept) 注射剂 8 毫克通过 FDA 批准用于治疗视网膜静脉阻塞后的黄斑水肿，并可在批准适应症中进行每月给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1132722384","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132722384?lang=zh_cn&edition=full","pubTime":"2025-11-20 05:11","pubTimestamp":1763586676,"startTime":"0","endTime":"0","summary":"Eylea Hd® (Aflibercept) 注射剂 8 毫克已获 FDA 批准，用于治疗视网膜静脉阻塞（Rvo）导致的黄斑水肿，并可在所有批准的适应症中进行每月给药。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023250504.SGD","BK4139","LU0058720904.USD","LU0889565916.HKD","LU0882574055.USD","LU0823434583.USD","LU1974910355.USD","LU2362540622.SGD","LU2106854487.HKD","LU2362541273.HKD","LU2362541513.USD","LU2089984988.USD","REGN","LU0823416689.USD","LU0289739699.SGD","LU0114720955.EUR","LU2237438978.USD","BK4585","LU2468319806.SGD","LU0320765992.SGD","LU0053666078.USD","LU1917777945.USD","BK4588","LU0109394709.USD","LU0823434740.USD"],"gpt_icon":0},{"id":"1158394635","title":"再生元制药公司杜比尤单抗关键试验达成所有主要和次要终点，显著减轻过敏性真菌性鼻窦炎症状；sBLA获得FDA优先审查","url":"https://stock-news.laohu8.com/highlight/detail?id=1158394635","media":"投资观察","labels":["policyRegulatory","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158394635?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:08","pubTimestamp":1763572090,"startTime":"0","endTime":"0","summary":"11月7日 - 再生元制药公司宣布：*杜比尤单抗（DUPIXENT®）关键试验达成所有主要和次要终点，显著减轻过敏性真菌性鼻窦炎（AFRS）的体征和症状；sBLA获得FDA优先审查*再生元制药公司：杜比尤单抗的sBLA已被美国FDA接受优先审查，目标行动日期为2026年2月28日。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN","LU1917777945.USD","LU0823434740.USD","LU0320765992.SGD","LU0889565916.HKD","BK4139","LU0823434583.USD","LU1974910355.USD","LU0053666078.USD","LU2237438978.USD","BK4585","LU2362541513.USD","LU2089984988.USD","LU0114720955.EUR","LU2468319806.SGD","LU0289739699.SGD","LU2106854487.HKD","LU0058720904.USD","LU0109394709.USD","LU0882574055.USD","LU0823416689.USD","BK4588","LU2023250504.SGD","LU2362540622.SGD","LU2362541273.HKD"],"gpt_icon":0},{"id":"1196287619","title":"再生元制药公司Libtayo®（Cemiplimab）在欧盟获得批准，成为首个也是唯一用于高复发风险的皮肤鳞状细胞癌术后及放疗辅助治疗的免疫疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1196287619","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196287619?lang=zh_cn&edition=full","pubTime":"2025-11-19 20:10","pubTimestamp":1763554234,"startTime":"0","endTime":"0","summary":"再生元制药公司Libtayo®（Cemiplimab）在欧盟获得批准，成为首个也是唯一用于高复发风险的皮肤鳞状细胞癌（Cscc）术后和放疗的辅助治疗免疫疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362540622.SGD","LU0823434740.USD","LU0109394709.USD","LU1974910355.USD","LU2089984988.USD","REGN","LU2362541273.HKD","LU2106854487.HKD","LU2237438978.USD","BK4585","LU0882574055.USD","BK4139","LU0289739699.SGD","LU0053666078.USD","BK4588","LU0058720904.USD","LU2468319806.SGD","LU1917777945.USD","LU0114720955.EUR","LU0320765992.SGD","LU2362541513.USD","LU0889565916.HKD","LU0823416689.USD","LU2023250504.SGD","LU0823434583.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":-0.0797},{"period":"1month","weight":-0.0223},{"period":"3month","weight":0.2681},{"period":"6month","weight":0.3512},{"period":"1year","weight":0.0574},{"period":"ytd","weight":-0.0503}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再生元制药公司于1988年在纽约州成立。再生元制药公司是一家完全集成的生物技术公司，它发现、发明、开发、制造和商业化治疗严重疾病的药物。其正在开发的商业化药物和候选产品旨在帮助患有眼疾、过敏性和炎症性疾病、癌症、心血管和代谢性疾病、疼痛、传染病和罕见疾病的患者。它的核心业务战略是在基础科学研究和发现启用技术方面保持坚实的基础，并建立在临床开发、制造和商业能力的基础上。其目标是继续成为一家综合性、多产品的生物技术公司，为患者和医疗专业人员提供预防和治疗人类疾病的重要选择。","yearOnYearQuotes":[{"month":1,"riseRate":0.514286,"avgChangeRate":0.036439},{"month":2,"riseRate":0.411765,"avgChangeRate":0.087815},{"month":3,"riseRate":0.470588,"avgChangeRate":-0.044318},{"month":4,"riseRate":0.470588,"avgChangeRate":0.017191},{"month":5,"riseRate":0.628571,"avgChangeRate":0.057479},{"month":6,"riseRate":0.428571,"avgChangeRate":0.006745},{"month":7,"riseRate":0.657143,"avgChangeRate":0.052646},{"month":8,"riseRate":0.542857,"avgChangeRate":0.022877},{"month":9,"riseRate":0.457143,"avgChangeRate":0.023281},{"month":10,"riseRate":0.4,"avgChangeRate":-0.00141},{"month":11,"riseRate":0.542857,"avgChangeRate":0.046018},{"month":12,"riseRate":0.485714,"avgChangeRate":0.043803}],"exchange":"NASDAQ","name":"再生元制药公司","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再生元制药公司,REGN,再生元制药公司股票,再生元制药公司股票老虎,再生元制药公司股票老虎国际,再生元制药公司行情,再生元制药公司股票行情,再生元制药公司股价,再生元制药公司股市,再生元制药公司股票价格,再生元制药公司股票交易,再生元制药公司股票购买,再生元制药公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}